Lung Adenocarcinoma treatment: Traditional therapy and Immunotherapy

Abstract

The previous years, the incidence of lung adenocarcinoma (LADC) has gradually increased. As a subset of non-small cell lung cancer (NSCLC), LADC is very severe (12% 5-year survival rate) and often occurs in people who have never smoked. With forward genetic research, scientists have found a series of related mutant genes. Among them, EGFR is the most common gene mutation in Asian LADC. This article systematically summarizes and analyzes the existing treatment methods and related clinical data for EGFR mutations in LADC and puts forward the prospect of feasible treatment methods in the future. This includes traditional chemotherapy and radiotherapy, targeted drug therapy (fifth generation and FDA-approved drugs), and immunotherapies.